28 related articles for article (PubMed ID: 10790998)
1. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
Konno H; Tanaka T; Baba M; Kanai T; Matsumoto K; Kamiya K; Nakamura S
Jpn J Cancer Res; 1999 Apr; 90(4):448-53. PubMed ID: 10363584
[TBL] [Abstract][Full Text] [Related]
2. [A case report of rectal cancer with liver and pulmonary metastases responding to TS-1].
Nishimura G; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1453-6. PubMed ID: 11681257
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
5. [Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Kitamura M; Arai K; Iwasaki Y; Takahashi T; Saitoh K; Fujii T; Shirasaka T
Gan To Kagaku Ryoho; 2000 Apr; 27(4):559-63. PubMed ID: 10790998
[TBL] [Abstract][Full Text] [Related]
6. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
7. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
8. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
9. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
10. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
